Fasciola hepatica-induced immune suppression of spleen mononuclear cell proliferation: role of nitric oxide.
The aim of the present study was to evaluate the proliferative response of spleen mononuclear cells (Spm) to mitogens in rats infected with Fasciola hepatica and its correlation with Spm and peritoneal cell (PC) nitric oxide (NO) production on Days 1, 3, 7, 14, 30, and 60 postinfection. In addition, histological changes in the liver were also studied. The proliferative response to Con A of F. hepatica-infected Spm was significantly decreased on Day 7 postinfection (P < 0.01). However, a pronounced increase of the proliferative response was detected from Day 3 until Day 60 when Spm were stimulated with LPS. In order to determine whether NO levels were modified during F. hepatica infections, we quantified nitrite in Spm and PC supernatants in cultures. Our results indicate a profound decrease of nitrite production by LPS-stimulated PC on the first and second weeks postinfection, and an increase in the levels of this mediator on LPS-stimulated Spm at the same postinfection time. The F. hepatica excretory-secretory antigen (ESA) was in part involved in the decrease of nitrite production by LPS-stimulated PC. A mechanism to avoid an immune response during the first stages of liver penetration could explain the transient suppression observed in Spm proliferative responses. On the other hand, the decrease in NO production by rat-infected PC could also be one of the strategies of the parasite to avoid the potential killing effect of NO during peritoneal migration.
Cervi
L
L
Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina.
Rossi
G
G
Cejas
H
H
Masih
D T
DT
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D002374:Catalase / Q000494:pharmacology; D003208:Concanavalin A / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005211:Fascioliasis / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006146:Guanidines / Q000494:pharmacology; D007108:Immune Tolerance; D007213:Indomethacin / Q000494:pharmacology; D008099:Liver / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000378:metabolism; D008297:Male; D009569:Nitric Oxide / Q000502:physiology*; D009573:Nitrites / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000166:cytology* / Q000276:immunology* / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D006146:Guanidines; D009573:Nitrites; D003208:Concanavalin A; D009569:Nitric Oxide; D002374:Catalase; C004479:pimagedine; D007213:Indomethacin